Ryu, Min-HeeMin-HeeRyuLee, Kyung HeeKyung HeeLeeShen, LinLinShenKUN-HUEI YEHYoo, ChanghoonChanghoonYooHong, Young SeonYoung SeonHongPark, Young IeeYoung IeeParkYang, Sung HyunSung HyunYangShin, Dong BokDong BokShinZang, Dae YoungDae YoungZangKang, Won KiWon KiKangChung, Ik-JooIk-JooChungKim, Yeul HongYeul HongKimRyoo, Baek-YeolBaek-YeolRyooNam, Byung-HoByung-HoNamPark, Young SooYoung SooParkKang, Yoon-KooYoon-KooKang2023-06-272023-06-272023-042045-7634https://scholars.lib.ntu.edu.tw/handle/123456789/633125In this randomized phase II study, we evaluated the efficacy and safety of sorafenib in combination with capecitabine and cisplatin (XP) as first-line chemotherapy in advanced gastric cancer.enVEGF; capecitabine; chemotherapy; cisplatin; gastric cancer; sorafenibjournal article10.1002/cam4.5536365150032-s2.0-85144080259https://api.elsevier.com/content/abstract/scopus_id/85144080259